Compare Ascendis Pharma A/S (ASND) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Remitly Global Inc — how do they compare? Ascendis Pharma A/S trades at $265.85 (market cap $17.74B), while Remitly Global Inc trades at $23.97 (market cap $5.01B). The key difference: Ascendis Pharma A/S is far larger — about 3.5× Remitly Global Inc's market cap. Which is the better fit depends on your goals.
| ASND | RELY | |
|---|---|---|
Market Cap | $17.74B | $5.01B |
Sector | Health | Technology |
52-Week High | $277.18 | $24.28 |
52-Week Low | $163.32 | $12.20 |
Enterprise Value | $18.11B | $4.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
RELY trades at $23.77, up 0.89% today, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q1 2026 EPS of $0.23, beating expectations, and raised full-year guidance to $1.96–$1.975 billion revenue. Recent news highlights a UAE license and market share gains.
Outlook is positive with 92% analyst buy ratings and a $26.75 consensus target, but high P/E of 49.52 and competitive pressures in remittance pose risks. Profitability has turned positive, with net income reaching $67.93M in 2025 after prior losses, signaling a sustainable growth trajectory if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
